Immitra Bio

Description

Immitra Bio develops an in‑vivo gene editing and stem cell therapy platform aimed at producing single, off‑the‑shelf injections to treat inherited blood disorders, advancing preclinical proof‑of‑concept studies and disease reversal models for patients with rare genetic diseases.

Related

• 21st.BIO A/SBuilds a precision fermentation technology platform providing strains, fermentation processes, and downstream workflows for…
• 3D Systems ($DDD)3D Systems provides 3D printers, materials, software and services for industrial manufacturing, healthcare, dental, jewelry, aerospace,…
• AbbelightAbbelight provides workflow solutions for biological imaging, sample preparation, and data analysis.
• Ability PharmaceuticalsAbilityPharma develops biopharmaceutical drug candidates. Its clinical pipeline targets cancer treatment, including ABTL0812 trials for…
• AbInitio BioAbInitio Bio builds an AI-native operating platform for drug development and manufacturing, helping teams assess developability, accelerate…
• AbridgeAbridge builds an AI assistant that turns clinical conversations into draft and billable documentation for clinicians, nursing teams, and…
• ACD PharmaACD Pharma develops bacteriophage-based biocontrol products and technologies for preventing and treating bacterial infections with…
• ACIES BIO d.o.o.Builds end-to-end solutions in microbial biotech for industrial customers needing strain development, bioprocess scale-up, downstream…
• ActitheraActithera develops targeted radioligand therapies by linking radioactive isotopes to designed molecules for delivery of radiation to…